Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201812-22 Development of new anticancer drug for treatment of Erbitux resistant colon cance(Oncology, Chemical) [2020-05-26]

Ongoing Project
Section Lead
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Erbitux is the representative targeted anticancer drug for colon cancer patients. Based on the discovering of primary overcoming factor for Erbitux resistance, we aim to develop a new drug for Erbitux resistant colon cancer patients with KRAS wild type. Moreover, we also present diagnosis of predictive biomarker.

Unmet Medical Need & Target Patients

1) Target patients

- Erbitux resistant colon cancer patient group with KRAS wild type gene

- Target protein expressing colon cancer group with KRAS mutant type gene

- Acquired resistant to Erbitux colon cancer patients


2) Unmet Medical Needs

- Colorectal cancer (CRC) is the third leading cause of mortality among cancer patients in the Korea, and it has recorded the second highest mortality rate in the world.

- Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world.

- There is a lack of radical surgery for metastatic colorectal cancer and 5yr survival rate for colon cancer is less than 5%. Therefore, the need for the breakthrough therapy is huge.

- Erbitux is the EGFR targeted therapeutic antibody and used for treatment of KRAS wild type colon cancer patients. Even some patient with wild-type K-Ras gene can be Erbitux non-responder by having BRAF, BRAS, PTEN and PI3K mutation. Currently, there is no treatment available for Erbitux resistant patient group with KRAS WT Gene, which is almost 50% of KRAS WT Gene holders.


- Establishment of diagnostic method for predictive biomarker on Erbitux non-responding colorectal cancer patients

- Selection of preclinical candidate compound & pharmacological analysis

- The efficacy analysis of preclinical candidate according predictive biomarker

- Analysis of predictive biomarker on colon cancer patients

- Preclinical studies for preclinical compound

- For expansion of indication, efficacy analysis based on predictive biomarker of preclinical candidate in vitro and in vivo xenograft model

Intellectual Property

- Product patent: 6 patents registered in Korea, 3 patents registered in foreign countries, 1 patent filed in Korea, and 1 patent filed in PCT

- Biomarker patent: 1 patent registered in Korea, 4 patents filed in foreign countries

- Target patent: 1 patent registered in Korea, 4 patents filed in foreign countries

Competitive Advantages

The First-in-class predictive biomarker for Erbitux non-response colon cancer patients

Contact & Company Overview

Related Project

Related Project